Background: Prostate cancer (PCa), is the second most prevalent solid tumor among men worldwide (7.3%), and the leading non-skin cancer in USA where it represents 14.9% of all new cancer cases diagnosed in 2024. This multifactorial disease exhibits substantial variation in incidence and mortality across different ethnic groups and geographic regions. Although prostate-specific antigen (PSA) remains widely used as a biomarker for PCa, its limitations reduce its effectiveness for accurate detection. Consequently, finding molecules that can either complement PSA and other biomarkers is a major goal in PCa research. Methods: Urine samples were collected from healthy donors (n = 5) and patients with low- and high-risk PCa (4 and 7 subjects, respectively) and were analyzed using proteomic data-derived systems and biology approaches. The most promising proteins were further investigated by means of The Cancer Genome Atlas (TCGA) database to assess their associations with clinical and histopathological characteristics in a larger in silico patient population. Results: By evaluating the variations in the urinary proteome as a mirror of the changes occurring in prostate tumor tissue, components of complement and coagulation cascades and glutathione metabolism emerged as hallmarks of low- and high-risk PCa patients, respectively. Moreover, our integrated approach highlighted new potential biomarkers, including CPM, KRT8, ITIH2, and RCN1. Conclusions: The good overlap of our results with what is already reported in the literature supports the new findings in the perspective of improving the knowledge on PCa. Furthermore, they increase the panel of biomarkers that could enhance PCa management. Of course, further investigations on larger patient cohorts are required.
Background: Prostate cancer (PCa) is the second most prevalent solid tumor among men globally and the leading non-skin cancer in American men. In 2020 alone, approximately 1.4 million new cases of prostate cancer were diagnosed worldwide, representing 14.1% of all new cancer cases in men. This multifactorial disease exhibits substantial variation in incidence and mortality across different ethnic groups and geographic regions. Although prostate-specific antigen (PSA) remains widely used as a biomarker for PCa, its limitations reduce its effectiveness for accurate detection. Consequently, finding biomarkers that can either complement or replace PSA is a major goal in PCa research. Methods: Urine samples were collected from healthy individuals (n=5) and patients with low- and high-risk PCa (4 and 7 subjects, respectively) and were analyzed using proteomic data-derived systems biology approaches. The most promising potential biomarkers were further investigated using The Cancer Genome Atlas (TCGA) database to assess their associations with clinical and histopathological characteristics in a larger in silico patient population. Results: In addition to describing the variations of the urinary proteome, the integration of protein profiles, network models and TCGA database has highlighted new potential biomarkers, including CPM, KRT8, ITIH2 and RCN1 that could enhance PCa management. Conclusions: Our findings support the technical feasibility of this combined approach for biomarker discovery and suggest further investigation into specific urinary proteins as potential novel biomarkers in larger patient cohorts.
16 June 2025 in International Journal of Pharmaceutics
Most in vivo studies on MSC-secretome for osteoarthritis (OA) have relied on animal models, using products lacking pharmaceutical quality, not formulated for clinical use, and insufficiently characterized, limiting knowledge of its effectiveness. This study reports veterinary clinical trials on dogs and horses with spontaneous OA: in dogs (26 subjects), the trial is randomized, double-blinded, and controlled; in horses, 5 clinical cases were treated for safety assessment. Treatment consisted of hyaluronic acid with either lyosecretome - a freeze-dried, injectable MSC-secretome obtained through standardized GMP manufacturing - or mannitol, the lyosecretome excipient (control), intrarticularly administered. Patients underwent clinical evaluations and orthopedic assessments over an 80-day follow-up; dog-owner feedback was collected through questionnaires. Lyosecretome doesn't induce systemic adverse responses. In dogs, improvement following treatment - significant in favor of lyosecretome - was observed, especially in reducing lameness; although it did not demonstrate significant pain reduction, patients were significantly more likely to walk, play, and move easily after exercise. Proteomic investigation supported these efficacy findings, revealing lyosecretome proteins involved in inhibiting protease and hyaluronidase, as well as in regulating immune response and inflammation, and those associated with cartilage regeneration and antioxidant activity. These results support the beneficial effect of MSC-secretome on joint disorders and offer insights that may be relevant to human patients, given the similarities in OA pathophysiology between humans and dogs or horses.
The demand for user-friendly applications to support biologists in analyzing high-throughput proteomics data remains a pressing challenge. Given the complexity and the multiple intermediate steps involved, this process is time-consuming and often requires specialized computational skills. To simplify and accelerate the exploration of proteomics data, we present PiProteline, an R package designed to operate on high-dimensional data matrices assembled from the output of any search engine commonly used in bottom-up proteomics experiments. In addition to data preprocessing and descriptive statistics, PiProteline enables label-free quantitation, functional enrichment, and systems biology analyses. It supports both unweighted and weighted protein–protein interaction (PPI) network topological analyses for the identification of critical nodes, such as hubs and bottlenecks. By integrating multiple computational approaches, PiProteline accelerates the selection of potentially relevant protein signatures, providing insights into the molecular mechanisms characterizing the investigated systems. This information facilitates the formulation of new hypotheses and the design of targeted experiments, ultimately reducing costs and advancing translational medicine. PiProteline is available as an open-source R package via GitHub, as a Shiny application, and via Zenodo.
The demand for user-friendly applications to support biologists in analyzing high-throughput proteomics data remains a pressing challenge. Given the complexity and the multiple intermediate steps involved, this process is time-consuming and often requires specialized computational skills. To simplify and accelerate the exploration of proteomics data, we present PiProteline, an R package designed to operate on high-dimensional data matrices assembled from the output of any search engine commonly used in bottom-up proteomics experiments. In addition to data preprocessing and descriptive statistics, PiProteline enables label-free quantitation, functional enrichment, and systems biology analyses. Notably, it supports both unweighted and weighted protein-protein interaction (PPI) network topological analyses for the identification of critical nodes, such as hubs and bottlenecks. By integrating multiple analytical approaches, PiProteline accelerates the selection of potentially relevant protein signatures, providing insights into the molecular mechanisms characterizing the investigated systems. This information facilitates the formulation of new hypotheses and the design of targeted experiments, ultimately reducing costs and advancing translational medicine. PiProteline is available as an open-source R package via GitHub (https://github.com/lomi95/PiProteline) and as a Shiny application (https://github.com/salehnhd/PiProteline-Shiny).
We present here the Co-expressed Protein-Protein Interactions (CoPPIs) algorithm. In addition to minimizing correlation-causality imbalance and contextualizing PPIs to the investigated systems, it combines PPIs and protein co-expression networks to identify differentially correlated functional modules. To test CoPPIs, we processed a set of proteomic profiles from different brain areas of controls and subjects affected by idiopathic Parkinson’s disease or carrying a GBA1 mutation. Its robustness was supported by the extraction of functional modules, related to translation and mitochondria, whose involvement in PD pathogenesis is well documented. Furthermore, the selection of hubs and bottlenecks from the weighted PPI networks provided molecular clues consistent with the PD pathophysiology. Of note, like quantification, the CoPPIs algorithm revealed less variations when comparing disease groups than when comparing diseased and controls. However, correlation and quantification results showed low overlap, suggesting the complementarity of these measures. An observation that opens the way to a new investigation strategy that takes into account not only protein expression, but also the level of coordination among proteins that cooperate to perform a given function.